DailyIQ
|
Sector:HealthcareAll sectors
Last updated 10 hours ago

WST·West Pharmaceutical Services, Inc.

$.
-. (-.%)
High
$329.86
Open
$329.55
Market Cap
23.17B
52W High
$336.82
Low
$326.11
P. Close
$327.95
P/E
42.69
52W Low
$206.80
Fwd P/E
34.32
DailyIQ Est.
$385.79
Technical Score (1D)
82
BUY
News Sentiment
78
BULLISH
West Pharmaceutical Services is currently viewed as potentially undervalued by roughly 6.9 % when benchmarked against the expanding GLP‑1 therapeutic market, a valuation that hinges on the company’s role in drug containment and delivery. This assessment follows a 35.85 % share‑price gain over the past three months, underscoring recent momentum that could translate into a short‑term upside if the GLP‑1 narrative holds. The company’s manufacturing expertise for GLP‑1 delivery systems positions it to capture projected demand growth, which could lift earnings in the next 1–10 trading days. The 52.46 % total shareholder return over the past year further signals that investors have already reaped significant value, suggesting a window for additional upside if the valuation thesis is validated. The key driver for the next trading week will be the release of quarterly earnings guidance, which will confirm whether the company can sustain its growth trajectory. Watch for any updates on GLP‑1 product approvals, as a new approval could accelerate revenue streams and validate the 6.9 % undervaluation estimate. Monitor partnership announcements or licensing deals that could expand WST’s reach into the GLP‑1 market, as such moves would reinforce the company’s strategic positioning. Finally, keep an eye on broader market sentiment toward specialty pharmaceutical manufacturers, as shifts in risk appetite could influence WST’s short‑term valuation dynamics.
Earnings Summary
West Pharmaceutical Services, Inc. is a global provider of containment and delivery systems for injectable drugs and healthcare products, operating through proprietary and contract‑manufactured product segments that supply stoppers, seals, syringes, and advanced drug delivery solutions such as Crystal Zenith, positioning it as a key partner for pharmaceutical and medical device companies in the medical instruments and supplies sector. In the most recent two quarters, the company posted EPS of $2.04 in Q4 2025 and $2.13 in Q1 2026, both beating estimates of $1.67 and $2.05 respectively, while revenue grew from $805 million to $844.9 million, a $39.9 million increase; the prior two quarters saw EPS rise from $1.84 to $1.96 and revenue from $766.5 million to $804.6 million, indicating a slight deceleration in EPS growth but consistent revenue momentum, with the company consistently beating analyst expectations in all seven quarters reported. Historically, West has demonstrated strong YoY growth, with revenue up 7.5% from Q4 2024 to Q4 2025 and 21% from Q1 2025 to Q1 2026, and EPS rising 12% and 47% over the same periods, underscoring a pattern of robust earnings expansion even as the company navigates a high‑margin specialty services model. Recent news highlights the firm’s upward revision of full‑year 2026 revenue and EPS guidance driven by accelerated growth in biologics‑related high‑value components and self‑injection delivery devices, a near‑term catalyst that has already spurred analyst upgrades and a $297.65 million share buyback, while a leadership transition slated for H2 2026 may influence strategic priorities; investors should watch for confirmation of the revised guidance and any regulatory updates that could impact the biologics pipeline, as well as potential supply‑chain constraints that could temper upside. Forward‑looking watch points include monitoring the next earnings release for guidance confirmation, assessing the impact of any new GLP‑1 product approvals, and observing how the leadership transition may shape future contract wins and capital allocation decisions.

EPS

EstBeatMiss
$1.13$1.41$1.69$1.98$2.26Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.08 - -
Q1'26$2.05$2.13+3.8%
Q4'25$1.67$2.04+22.1%
Q3'25$1.71$1.96+14.6%
Q2'25$1.54$1.84+19.7%
Q1'25$1.26$1.45+15.3%

Revenue

EstBeatMiss
$676M$724M$772M$821M$869MQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$847M - -
Q1'26$835M$845M+1.2%
Q4'25$773M$805M+4.1%
Q3'25 - $805M -
Q2'25 - $767M -
Q1'25 - $698M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

WST Stock Snapshot

WST is currently trading at $326.18, giving West Pharmaceutical Services, Inc. a market cap of 23.17B and a P/E ratio of 42.7. Today's range spans $326.11–$329.86, with shares opening at $329.55 and moving down $1.77 (0.5%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 78/100.

Over the past year WST has traded between $206.80 and $336.82 - the current price is +57.7% off the 52-week low and -3.2% from the high. 24 analysts cover the stock with a Buy consensus and a mean 12-month target of $358.79 (range $310.00–$400.00), implying upside of +10.0%.

Short interest data on large-cap Healthcare names like WST (23.17B market cap) becomes relevant when the technical picture turns bullish - a BUY on 82/100 with bullish sentiment (78/100) is exactly the kind of setup that makes shorts nervous. Price at $326.18 (near 52-week highs in $206.80–$336.82). The current P/E ratio stands at 42.7. Short covering in a bullish technical phase can add a secondary momentum layer on top of genuine long-side conviction - a dynamic worth monitoring in the current setup.

The combination of a BUY signal (82/100) and bullish news sentiment (78/100) puts WST on the screens of active managers who run quality-momentum overlays — a cohort that can build meaningful positions at 23.17B in Healthcare market cap without immediately moving the stock. At $326.18 (near 52-week highs in the $206.80–$336.82 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.